Clinical and Echocardiographic Outcomes After Implantation of the ALLEGRA Transcatheter Valve Using the Fully Repositionable IMPERIA Delivery System: One‐Year Results of the EMPIRE I Study Authors: José Antonio Baz, Claire B Ren, Christof Burgdorf, Christian Frerker, Ignacio Cruz‐González, Joan Antoni Gómez, José Maria Hernândez, Pilar Jimenez, Ernest Spitzer, Pim Tonino, Pieter Vriesendorp, Nicolas van Mieghem, Samuel Copt, Anders Jönsson, Keith G Oldroyd, Nicolas Doll Published: 2026 ABSTRACT ABSTRACTBackgroundThe EMPIRE I study assessed the early (30 days) safety and efficacy of a new fully repositionable delivery system (IMPERIA) for the commercially available ALLEGRA transcatheter aortic valve in patients with either severe native aortic stenosis or a degenerated surgical bioprosthesis.AimTo report the final 1‐year results of the EMPIRE I study.MethodsEMPIRE I is a pre‐market, prospective, multi‐center, single‐arm study conducted at 11 centers in 3 European countries. There were independent data safety and clinical events committees and an independent echocardiographic core laboratory. In this analysis, VARC‐3 definitions of all clinical endpoints and echocardiographic parameters were employed.ResultsThe study recruited 121 patients with severe native aortic stenosis and 16 with degenerated surgical bioprosthesis. At 1 year, the incidence of bioprosthetic valve dysfunction in the native population was 5.9%. No patients developed structural valve deterioration or endocarditis, and there were no patients with haemodynamic valve deterioration or bioprosthetic valve failure. In the valve‐in‐valve sub‐group, 2/14 (14.3%) patients had moderate patient prosthesis mismatch at 30 days with no evidence of new bioprosthetic valve dysfunction at 1 year. In the native population, new permanent pacemaker implantation was 14.3% at 30 days and remained unchanged at 1 year. Cardiovascular mortality was 6.8% in the native population and 0% in the valve‐in‐valve patients. At 1‐year, all‐cause mortality was 10.8% (95% CI 6.4%−17.8%) in the native aortic stenosis population and 0% in the valve‐in‐valve patients.ConclusionAfter 1 year of follow‐up, the results of the EMPIRE 1 study show excellent haemodynamic performance, a low rate of bioprosthetic valve dysfunction, and no bioprosthetic valve failure in patients treated with the ALLEGRATM trans‐catheter aortic valve implanted using the new IMPERIATM fully repositionable delivery system.Keywords: aortic valve stenosis, self‐expanding heart valve, transcatheter aortic valve replacement Abbreviations aortic stenosis effective orifice area New York heart association pressure gradient patient prosthesis mismatch paravalvular regurgitation surgical aortic bioprostheses transcatheter aortic valve implantation transcatheter heart valve valve in valve Introduction The ALLEGRA trans‐catheter aortic valve is a self‐expanding supra‐annular bovine pericardial valve and has been commercially available since 2017. It has the shortest frame height of any of the available self‐expanding valves with large effective orifice areas (EOA), resulting in very low levels of patient prosthesis mismatch (PPM), even in challenging situations such as small native annuli and valve‐in‐valve (ViV) cases. In addition, it has several features designed to facilitate maintaining coronary access, including large cell sizes above and gold markers at the new valve plane. The first‐generation delivery system allows retrieval of the valve after the inflow has been opened and prior to final release, but does not allow repositioning in situ. In the EMPIRE I study, the early safety and efficacy of a new fully repositionable delivery system (IMPERIA) for the ALLEGRA valve was confirmed with successful repositioning performed in around half of the patients, no valve embolisations and no requirement for a second valve. The hemodynamic benefits of the valve were also demonstrated with a complete absence of moderate or severe PPM in the native aortic stenosis (AS) patients and only 2/16 patients with moderate PPM in the ViV cohort [1]. Now we report the 1‐year outcomes of the EMPIRE I study. Methods Patients Patient selection and the study design of the EMPIRE I trial have been described previously [1]. Patients with either symptomatic severe calcific AS, defined according to VARC‐2 [2], or a degenerated surgical bioprosthesis were enrolled after eligibility had been confirmed by a central screening committee (CSC). Patients were considered enrolled after informed consent was signed, all eligibility criteria were met and confirmed by the local heart team, participation had been approved by the CSC, and vascular access had been obtained. Study Device and Procedure All patients were treated with the commercially available ALLEGRA valve, which has 3 sizes (23, 27, and 31 mm), allowing treatment of patients with an annulus diameter range of 16.5 to 27.0 mm and an upper perimeter limit of 85 mm. The new IMPERIA delivery system tested in this study has an integrated wire reinforced sheath with a hydrophilic coating and a winding mechanism to progressively open the valve from inflow to outflow and re‐capture it if repositioning is required. Patients were assessed at baseline, during the procedure, at discharge, 30 days, 6 and 12 months. Pre‐dilatation in the native AS cohort was mandatory per protocol. Study Design and Oversight One hundred seventy‐six patients were screened between January and November 2023. Subsequently, a total of 121 patients with native AS and 16 patients with degenerated surgical bioprostheses were enrolled in the study between January and November 2023. The sponsor (Biosensors Europe, Morges, Switzerland) designed the study in collaboration with the principal investigators and provided funding. Clinical site selection, data collection, and monitoring were conducted by an independent clinical research organization contracted by the sponsor (Cardialysis, Rotterdam, The Netherlands), which also acted as the echocardiographic core laboratory for the study. All core laboratory analyzes were performed according to established guidelines [3]. Statistical analyzes were carried out by the sponsor. The manuscript was prepared by the investigators in conjunction with the sponsor. The data supporting our conclusions will be made available by the sponsor upon reasonable request. All listed authors attest to the completeness and accuracy of all data and to adherence to the study protocol. The Ethics Committee at each site approved the trial, and written informed consent was obtained from all patients. Study End Points The primary endpoint was the rate of device success according to the Valve Academic Research Consortium 2 (VARC‐2) [2] definition at discharge from the index procedure or 7 days post‐implant (whichever came first). Secondary endpoints included procedural success, assessment of functional status, and the need for new permanent pacemaker implantation. For the analysis presented here, we have utilized the VARC‐3 definitions of device success and all echocardiographic parameters [4]. In the VARC‐3 definition of device success, the time‐point for assessment is at 30 days, and within the composite of intended valve performance, PPM has been removed and replaced by Doppler velocity index (DVI). Statistical Analysis and Power Calculation For the primary endpoint of device success, a performance goal was calculated from the results of the Evolut R (Medtronic Inc) CE Mark study [5]. The analysis group for this report comprised the 137 patients who underwent attempted implant of the ALLEGRA transcatheter aortic valve with the IMPERIA delivery system. Baseline categorical variables are presented as percentages and continuous variables as mean ± SD or median (interquartile range). Clinical events are constructed from Kaplan‐Meier estimates and corresponding 95% confidence intervals using the log‐log method. Patients were censored at death, withdrawal from study, scheduled end of study, or 365 days post‐enrollment, whichever occurred first. There was no imputation for missing data except for the primary endpoint. If any of the echocardiographic parameters in the VARC‐2 device success definition were missing at discharge (iEOA, mean gradient, or regurgitation), then the value at 30 days was used if available. For the primary endpoint of device success, a performance goal was calculated from the results of the Evolut R (Medtronic Inc) CE Mark study [5]. The primary endpoint was analyzed using a two‐sided Clopper‐Pearson exact test. A sensitivity analysis with complete cases only was also undertaken. Bioprosthetic valve dysfunction percentages are reported as cumulative incidence to account for the competing risk of death. We also performed a multivariate analysis to assess the effect of potential predictors on the primary endpoint of VARC‐2 and VARC‐3 device success at 30 days. Adjusted odds ratios were calculated using multivariable logistic regression, including baseline and CT variables that were selected based on their potential influence on the outcomes. Finally, we performed a comparison of outcomes in patients with aortic annulus areas < 430 versus > 430 mm2. Results Patients Of 137 patients treated with an ALLEGRA valve, 132 (96.4%) were followed until death or 1‐year post procedure. Three patients withdrew before study completion, and 2 were lost to follow‐up. Baseline characteristics are shown in Table 1. The average age in the native AS and ViV cohorts was 82.2 ± 5.0 and 80.0 ± 5.3 years, 67.8% and 31.2% were female, and 54.5% and 75.0% were in NYHA class III or IV. More than 50% of patients were on aspirin at baseline in both cohorts, and the percentage of patients on dual antiplatelet therapy was 9.9% in the native AS cohort and 12.5% in the ViV cohort. Table 1Baseline characteristics.Native (N = 121)ViV (N = 16)Age (years)82.2 ± 5.080.0 ± 5.3Gender (Female)67.8% (82)31.3% (5)STS score (%)4.1 ± 2.811.1 ± 15.1EuroSCORE II (%)3.7 ± 2.516.6 ± 19.7NYHA class III/IV54.5% (66)75.0% (12)COPD or chronic lung disease5.0% (6)18‐8% (3)Cerebrovascular disease5.8% (7)6.3% (1)Previous myocardial infarction12.4% (15)18.8% (3)Previous PCI16.7% (5)18.8% (3)Previous CABG4.1% (5)43.8% (7)LBBB/RBBB7.4% (9)37.5% (6)Pre‐existing pacemaker/ICD7.4% (9)18.8% (3)Atrial fibrillation or flutter28.1% (34)25.0% (4) Cardiac medications Aspirin42.1% (50)62.5% (10)P2Y12 inhibitors13.2% (16)25.0% (4)Oral anticoagulant24.8% (30)25.0% (4)Dual antiplatelet therapy9.9% (12)12.5% (2)Abbreviations: CABG = coronary artery bypass grafting, COPD = chronic obstructive pulmonary disease, ICD = implantable cardioverter‐defibrillator, LBBB = left bundle branch block, NYHA = New York Heart Association, PCI = percutaneous coronary intervention, RBBB = right bundle branch block, STS = Society of Thoracic Surgeons. Baseline characteristics. Abbreviations: CABG = coronary artery bypass grafting, COPD = chronic obstructive pulmonary disease, ICD = implantable cardioverter‐defibrillator, LBBB = left bundle branch block, NYHA = New York Heart Association, PCI = percutaneous coronary intervention, RBBB = right bundle branch block, STS = Society of Thoracic Surgeons. Device Success at 30 Days The primary endpoint of device success at 7 days according to VARC‐2 has been previously reported and was achieved in 91.9% of the intention‐to‐treat native AS cohort (95% CI 83.5%−100.0%; p < 0.001 vs. performance goal) [1]. By VARC‐3 criteria (Table 2), at 30 days, technical success was achieved in 94.2% (114/121) of the native AS patients and 100% (16/16) of the ViV patients. Freedom from mortality was 98% in the native AS patients and 100% in the ViV patients. Freedom from surgery or intervention related to the device or to a major vascular or access‐related or cardiac structural complication was 95% in the native AS patients and 100% in the ViV patients. Regarding intended valve performance, no patients in either cohort had a mean pressure gradient (MPG) > 20 mmHg or a peak velocity > 3 m/s or a DVI < 0.25. At 30 days, 10/107 (9.3%) patients in the native AS cohort had moderate aortic regurgitation with no cases of severe aortic regurgitation. One patient in the ViV cohort had moderate or severe aortic regurgitation. Accordingly, VARC‐3 device success was achieved in 82.9% (87/105) of the native AS patients and 92.9% (13/14) of the ViV patients. Table 2VARC−3 device success.Native (N = 121)ViV (N = 16)Technical success114/121 (94.2%)16/16 (100%)Freedom from mortality119/121 (98.3%)16/16 (100%)Freedom from surgery or intervention related to the device or to a major vascular or access‐related or cardiac structural complication115/121 (95.0%)16/16 (100%)Intended performance of the valve90/100 (90.10%)13/14 (192.9%)Mean gradient < 20 mmHg101/101 (100%)14/14 (100%)Peak velocity < 3 m/s101/101 (100%)14/14 (100%)Less than moderate aortic regurgitation97/107 (90.7%)13/14 (92.9%)Doppler velocity index ≥ 0.25100/100 (100%)14/14 (100%)Device Success87/105 (82.9%)13/14 (92.9%) VARC−3 device success. We performed a multivariate analysis to identify predictors of VARC‐2 and VARC‐3 device success. The selected variables were age, body mass index, total calcium score, valve size, annulus area, annulus diameter, LVOT area, LVOT diameter, sino‐tubular junction area, and sino‐tubular junction diameter. In summary, no independent predictors were identified (Supporting Information S1: Tables 1–2). Echocardiographic Outcomes at 1 Year At 1 year, MPG was 8.7 ± 3.4 mmHg in the native AS cohort and 9.9 ± 2.5 mmHg in the ViV cohort. EOA were 2.0 ± 0.4 cm2 in the native AS cohort and 1.7 ± 0.2 cm2 in the ViV cohort (Table 3 and Figure 1). By the VARC‐3 criteria, there were no native AS patients with any degree of PPM. In the ViV cohort, 2/14 patients (14.3%) had moderate PPM. At 1‐year, moderate PVR was present in 6/91 patients (6.6%) in the native AS cohort and in none of the ViV patients. There were no cases of severe PVR in either cohort at any time point. In a paired analysis of native AS patients with analyzable echocardiograms at both 30 days and 1 year, the rates of none/trace, mild, and moderate PVR were 31.8%, 61.4%, and 6.8% at 30 days and 58.0%, 37.5%, and 4.5% at 1 year (Supporting Information S1: Table 3). Table 3Echocardiographic outcomes according to VARC ‐3.Native (N = 121)ViV (N = 16) Baseline Mean pressure gradient, mmHg44.8 ± 13.4 (119)34.8 ± 18.1 (16)Maximum aortic velocity, m/s4.2 ± 0.6 (119)3.7 ± 0.9 (16)Effective orifice area, cm2 0.6 ± 0.2 (111)0.8 ± 0.2 (12)Effective orifice area index cm2/m2 0.4 ± 0.1 (111)0.4 ± 0.1 (12) 1 year Mean pressure gradient, mmHg8.9 ± 3.6 (92)9.7 ± 2.4 (14)Maximum aortic velocity, m/s2.0 ± 0.4 (92)2.1 ± 0.3 (14)Effective orifice area, cm2 2.0 ± 0.2 (81)1.7 ± 0.2 (13)Effective orifice area index cm2/m2 1.1 ± 0.2 (81)1.0 ± 0.2 (13)Paravalvular regurgitation n = 91 n = 14None or trace57.1% (52)78.6% (11)Mild36.3% (33)21.4% (3)Moderate6.6% (6)0.0% (0)Severe0.0% (0)0.0% (0) Echocardiographic outcomes according to VARC ‐3. Echocardiographic outcomes (A) effective orifice area, (B) mean gradient, and (C) paravalvular leak. [Color figure can be viewed at wileyonlinelibrary.com] Bioprosthetic Valve Dysfunction and Failure at 1 Year At 1 year, in the native population, the incidence of bioprosthetic valve dysfunction was 7.7%, consisting of six patients with non‐structural valve deterioration (all moderate PVR by VARC‐3 criteria), one patient with probable valve thrombosis, and no patients with any degree of PPM. There were no patients with structural valve deterioration, endocarditis, haemodynamic valve deterioration, or bioprosthetic valve failure. In the ViV sub‐group, there was no additional evidence of bioprosthetic valve dysfunction. Clinical Outcomes at 1 Year After 1 year of follow‐up, 13 patients had died in the native AS cohort (10.8%). Of these, 8 (6.8%) were adjudicated as cardiovascular deaths by the independent clinical events committee. There were no deaths in the ViV cohort. The rate of disabling stroke was 4.3% in the native AS cohort and 6.3% in the ViV cohort. Life‐threatening bleeding occurred in 6 native AS patients (5.0%) and no ViV patients. There were no new pacemaker implantations in either cohort between 30 days and 1 year, resulting in new pacemaker rates of 14.3% in the native AS cohort and 0% in the ViV cohort (see Table 4 for the Kaplan‐Meier estimates and 95% confidence intervals). Table 4Clinical events at 1 year.Native (n = 121)ViV (n = 16)All‐cause mortality10.8% (13) [6.4%−17.8%]0.0% (0)Cardiovascular mortality6.8% (8) [3.5%−13.2%]0.0% (0)Disabling stroke4.3% (5) [1.8%−10.1%]6.2% (1) [9.1%−21.9%]Non‐disabling stroke1.7% (2) [0.4%−6.5%0.0% (0)Myocardial infarction0.0% (0)0.0% (0)Life‐threatening bleeding5.0% (6) [2.3%−10.9%]0.0% (0)Acute kidney injury: stage 2 or 30.0% (0)0.0% (0)Coronary artery obstruction0.0% (0)0.0% (0)Major vascular complications2.6% (3) [0.8%−7.8%]0.0% (0)Minor vascular complications6.6% (8) [3.4%−12.8%]0.0% (0)Valve‐related dysfunction requiring repeat procedure0.0% (0)0.0% (0)New pacemaker implantation14.3% (17) [9.1%−21.9%]0.0% (0) Note: Percentages are Kaplan−Meier estimates with 95% confidence intervals Clinical events at 1 year. Note: Percentages are Kaplan−Meier estimates with 95% confidence intervals Health Status KCCQ‐OS at baseline was 58.2 ± 23.8 in the native cohort and 50.6 ± 25.9 points in the ViV group. At 30 days, there was an absolute improvement of 16.7 ± 23.1 in the native AS cohort and of 42.3 ± 26.1 in the ViV cohort (Figure 2). Those improvements were maintained up to 1 year and in the native patients, 44.8% had a substantial improvement at 1 year (improvement of 20 points or more compared to baseline). NYHA class showed similar improvements over time in both cohorts. Functional improvement. [Color figure can be viewed at wileyonlinelibrary.com] Outcomes in Native AS Patients With Small Annuli The distribution of EOA and MPG according to annulus size is shown in Figure 3. Annulus area in native AS patients ranged from 280−550 mm2 with a mean of 425 ± 62 mm2 and a median of 428 mm2 indicating a symmetrical distribution. In native AS patients with an annulus area < 430 mm2 (mean 375 mm2), MPG at 1 year was 8.6 ± 3.1 mmHg, and EOA was 1.95 ± 0.19 cm2. T The rate of VARC‐3 device success at 30 days was 88.9% (48/54) in patients with an annulus area < 430 mm2 compared to 76.4% (39/51) in patients with an annulus area greater than 430 mm2 (p = 0.09). The rate of bioprosthetic valve dysfunction at 1 year was 3.6% (2/55) in patients with an annulus area < 430 mm2 consisting of one patient with moderate PVR and one patient with probable valve thrombosis. Echocardiographic outcomes by annulus size (A) Kansas City Cardiomyopathy Questionnaire (KCCQ) score and (B) New York Heart Association (NYHA) classification. [Color figure can be viewed at wileyonlinelibrary.com] Discussion The EMPIRE I study shows excellent haemodynamic performance of the ALLEGRA transcatheter aortic valve 1 year after implantation using the new fully repositionable IMPERIA delivery system. There was no evidence of structural valve deterioration or bioprosthetic valve failure. The clinical investigation protocol for the EMPIRE I study stipulated that the primary endpoint of device success would be defined according to VARC‐2, as the performance goal was derived from a study that utilized VARC‐2 definitions. These have now been superseded by VARC‐3, with one of the main differences being related to the reporting of PPM. In addition to modifying the definition of moderate and severe PPM according to body mass index, PPM (and PVR) have been reclassified as components of non‐structural bioprosthetic valve dysfunction. In addition, VARC‐3 defines 3 stages of haemodynamic valve deterioration with an emphasis on temporal change and 3 stages of clinical bioprosthetic valve failure [4, 6]. For the primary endpoint of EMPIRE 1, switching from VARC‐2 to VARC‐3 makes no material difference. In the VARC‐3 definition of device success, for the category of intended performance of the valve, PPM is replaced by DVI, but just as there were no native AS patients with moderate or severe PPM following valve implantation in EMPIRE I, similarly, there were no patients with DVI < 0.25. Considering bioprosthetic valve dysfunction, there were no patients in this study with evidence of structural valve deterioration at 1 year. Within the classification of non‐structural valve dysfunction, in the native AS cohort, there were four patients with moderate PVR, although it should be noted that this was defined by VARC‐2 criteria. The single case of probable valve thrombosis was diagnosed approximately 11 months post‐procedure in a native AS patient presenting with a minor stroke who was already on treatment with apixaban due to permanent atrial fibrillation and prior stroke. Echocardiography at a non‐study center showed an increased gradient across the bioprosthetic valve with appearances suggestive of leaflet thrombosis. This patient was switched from apixaban to warfarin, and 2 months later, the transvalvular gradient on echocardiography performed at the study center was lower than reported immediately post‐procedure. Unfortunately, the imaging from the non‐study center was never made available to the core laboratory, and multi‐slice cardiac CT was not performed, hence the adjudication by the clinical events committee of probable rather than definite valve thrombosis. Given the history of ongoing thrombotic events despite treatment with apixaban, there may have been a pro‐thrombotic state in this patient. Finally, there were no cases of endocarditis during the first year after valve implantation in any patient and, importantly, no bioprosthetic valve failure. In the original report of the primary endpoint of the EMPIRE I study, for the ViV population, we reported no patients with severe PPM and 2/16 patients with moderate PPM, consistent with the results of prior studies using the first‐generation delivery system [7, 8]. By comparison, in the randomized LYTEN trial, the rates of severe PPM were 66% in the balloon‐expandable group and 44% in the self‐expanding group [9]. We also reported the absence of PPM in native AS patients, despite more than half of the patients having a small native annulus as defined in the SMART [10] trial by an annulus area < 430 mm2. This was the case for both the VARC‐2 (at 7 days) and VARC‐3 (at 30 days) definitions of PPM. By comparison, the rates of moderate/severe PPM in the randomized SMART trial at 30 days were 10.3% in the self‐expanding cohort (Evolut PRO/PRO+/FX; Medtronic) and 35.1% in the balloon‐expandable cohort (SAPIEN 3/3 Ultra; Edwards Lifesciences), with rates of severe PPM being 1.7% and 7.1%, respectively. These outcomes contributed to rates of the co‐primary endpoint of bioprosthetic valve dysfunction at 1 year in the SMART trial of 9.4% in the self‐expanding group and 41.6% in the balloon expandable group [10]. These differences between platforms in the SMART trial persisted at 2 years, but there were still no differences in clinical endpoints (Data presented at CRT, March 2025). The current version of the ALLEGRA valve used in this study does not have an external sealing skirt, and this may potentially lead to less effective annular sealing, especially in heavily calcified anatomies. In the 1‐year results of the LANDMARK trial, the rate of moderate/severe PVR in the Evolut arm was 4.3% [11]. In the Evolut arm of the ACURATE IDE trial, the rate of moderate/severe PVR at 1 year was 4.6% [12]. Notwithstanding that these studies employed different echocardiographic core laboratories, the rates of moderate/severe PVR are close to the rate of 4.5% in our paired analysis, albeit a little lower than the rate of 6.6% for all native AS patients at 1 year. In this respect, it should be noted that severe calcification was not an exclusion criterion in EMPIRE I, and the mean volumetric calcium score in the native AS patients of 843 mm3 confirms that approximately half of the patients had severe calcification. In this context, and given the absence of an external sealing skirt, it could be argued that the PVR rates are perhaps better than might have been expected. Possible explanations include good conformability of the inflow of the valve frame to the native annulus and the ability to safely perform post‐dilatation, given the barrel‐shaped stent frame with no waist. Nonetheless, the next generation of the valve does have an external sealing mechanism and is the subject of ongoing clinical trials. The new pacemaker rate at 1 year was 14.3%, with no new pacemakers between 30 days and 1 year. This is lower than the new pacemaker rate of 18.9% at 1 year in the Evolut arm of the LANDMARK trial and similar to the rate of 14.1% in the Evolut arm of the ACURATE IDE trial [11, 12]. We recommended the use of the cusp overlap view to assess initial implant depth and encouraged operators to try to implant higher than had been recommended with the 1st generation non‐repositionable delivery system. However, at this time, we have no data on the relationship between pacemaker rates and either implant depth or over‐sizing. It may be the case that mandatory pre‐dilatation contributed to some of the conduction disturbances observed, but we believe this also contributed to the excellent haemodynamic outcomes observed. This study was not powered for clinical outcomes but the 95% confidence intervals for all‐cause mortality, cardiovascular mortality, and stroke overlap with those of comparable contemporary TAVI trials [11, 12, 13]. Limitations This is a small single‐arm study with follow‐up to only 1 year. In particular, the ViV cohort was only 16 patients. Cross‑study comparisons should be interpreted with caution, particularly when involving small studies. Accordingly, these comparisons are presented for descriptive purposes only and do not have any statistical validity. Longer‐term, larger studies are needed to confirm valve durability, as are randomized head‐to‐head comparisons with other TAVI devices. Conclusions After 1 year of follow‐up, the results of the EMPIRE 1 study show excellent haemodynamic performance, a low rate of bioprosthetic valve dysfunction, and no bioprosthetic valve failure in patients treated with the ALLEGRATM trans‐catheter aortic valve implanted using the new IMPERIATM fully repositionable delivery system. Ethics Statement The study was performed according to the Declaration of Helsinki and ISO 14155:2020. It was approved by the ethics committees of participating centers, and all patients provided written informed consent before enrolling into the study. Conflicts of Interest Dr. Spitzer declares institutional contracts/grants for which he receives no direct compensation from Abbott; Biosensors Europe SA, Boston Scientific; Edwards Lifesciences; Medtronic; Mixin Medtech (Suzhou) Co. Ltd.; Shanghai Microport Medical Co. Ltd.; NVT GmbH; Philips Healthcare; Pie Medical Imaging; Shanghai Shenqi Medical Technologies Co. Ltd.; and Siemens Healthcare GmbH. Dr. Spitzer declares being board member of Cardialysis, European Cardiovascular Research Institute, EU‐MDR Cardiovascular Collaboratory, and Academic Research Consortium. Dr. Ren reports institutional contracts for echocardiography core laboratory analyzes with Boston Scientific, Edwards Lifesciences, and NVT GmBH/Biosensors, for which she has received no personal compensation and has received honoraria from Abbott. Dr. Doll reports honorarium and travel by Biosensors. Dr. Frerker received honoraria and travel support from Biosensors and Bluesail Medical. Dr. Tonino declares research grants form Opsens, Biosensors, and lecture fees from Medtronic. Dr. Vriesendorp reports consultancy fees from Abbott, Biosensors, and Boehringer Ingelheim all paid to the institution. Dr. Cruz Gonzalez is a proctor and consultant for Boston, Medtronic, Biosensors, and SMT. Dr. Jimenez is a proctor for Abbott and Edwards Lifesciences. Samuel Copt, Anders Jönsson are employees of Biosensors International. Prof. KG Oldroyd has a consultancy agreement with Biosensors International. Dr. Baz is proctor for Abbott, Medtronic, and Biosensors and consultant for Medtronic and Biosensors. Nicolas Van Mieghem has received institutional research grant support from Abbott Vascular, Boston Scientific, Medtronic, Teleflex, and advisory fees from Abbott Vascular, Boston Scientific, Medtronic, Teleflex, JenaValve, Anteris, Siemens, and Materialize. The other authors declare no conflicts of interest. Supporting information Table S1: Multivariate Adjusted Analysis for VARC‐2 Device success. Table S2: Multivariate Adjusted Analysis for VARC‐3 Device success. Table S3: Echocardiographic outcomes – paired analysis. Acknowledgments This study was sponsored and funded by Biosensors Europe SA. References Associated Data Supplementary Materials Table S1: Multivariate Adjusted Analysis for VARC‐2 Device success. Table S2: Multivariate Adjusted Analysis for VARC‐3 Device success. Table S3: Echocardiographic outcomes – paired analysis.